News
中文
取消
News
2020-09-23 16:26:18
Company
Minoryx and Sperogenix ink an exclusive license agreement to develop and commercialize leriglitazone in China
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
2020-09-17 15:12:40
Company
Mr. Ziyu YAN delivered a keynote speech at the 9th China Rare Disease Summit
Mr. Yan Zhiyu was invited to attend the 9th China Rare Disease Summit held in Chengdu on 12 September and delivered a keynote speech on promoting China's participation in international multi-center clinical trials to accelerate orphan drugs access to China.